ClinicalTrials.gg
RecruitingNCT06173076Updated Aug 27, 2025

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

An observational study in Autoimmune Encephalitis and Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis, sponsored by Shen Chun-Hong. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Shen Chun-Hong · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Autoimmune Diseases of the Nervous System with a site in China — 18 open to participants now, 20 under way, 3 of them phase 3. Autoimmune Diseases of the Nervous System · China.

Planned enrollment
12th of 13
60 · median 300
Started
2022
with 3 others
Observational
13 of 26
9 open now
Primary completion
2027-12
later than 11 of 19 live
Registered
8th of 26
by date
Lead sponsor
3 of 26
Shen Chun-Hong

Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2022, is one of 13 observational ones, reaches primary completion later than 11 of the 19 other live ones, and was the 8th registered.

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

Browse Autoimmune Diseases of the Nervous System studies →

Open to participants now

18 of the 26 studies in Autoimmune Diseases of the Nervous System with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Autoimmune Diseases of the Nervous System with a site in China, or all of them as a file.
02

Study summary

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases.

So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.

Read the detailed description

In this prospective study, the investigators are aiming to recruit newly diagnosed patients with anti-LGI1 encephalitis. At the acute stage and during the follow-up, some routine and advanced paraclinical examinations will be conducted, including dynamic blood and/or cerebrospinal fluid (CSF) test, multimodal brain magnetic resonance imaging (MRI) including functional MRI, diffusion tensor imaging, arterial spin labeling, et al), Electroencephalography (EEG) or continuous video-EEG (VEEG), positron emission tomography (PET), neuropsychological tests and some other paraclinical examinations. Through the comprehensive analysis, the clinical outcomes and associated factors are further explored in anti-LGI1 encephalitis.

03

Conditions studied

  • Autoimmune Encephalitis
  • Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

the patients with anti-LGI1 encephalitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis.
  2. Newly diagnosed, and during the acute stage before study enrollment.
  3. Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. with the diagnosis of epilepsy, stroke, cerebral trauma, and/or other nervous system disease prior to the onset of encephalitis.
  2. with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody.
  3. Lost to follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. seizure outcomes

    The incidence of different seizure outcomes and associated factors will be analyzed.

    Time frame: 1 year, 2 year

  2. Clinical severity and recovery 1

    modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome

    Time frame: 1 year, 2 year

  3. Clinical severity and recovery 2

    clinical assessment scale for autoimmune encephalitis, ranging from 0-27, higher scores mean a worse outcome

    Time frame: 1 year, 2 year

  4. Incidence of recurrence

    a relapse of encephalitis

    Time frame: 1 year, 2 year

Secondary outcomes

  1. Memory assessment 1

    the Wechsler Memory Scale, high score means a good memory.

    Time frame: 1 year, 2 year

  2. Memory assessment 2

    Rey Auditory Verbal Learning Test (RAVLT), high score means a good vebal episodic memory.

    Time frame: 1 year, 2 year

  3. Brain volume

    with 3T magnetic resonance imaging (MRI), volumes of the whole hippocampus, hippocampal subfields and other relevant regions were determined using FreeSurfer. The unit of volume is described as mm3.

    Time frame: 1 year, 2 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

Of 28 observational studies under Autoimmune Diseases of the Nervous System, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 17. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Dec 15, 2023
StartActual
May 18, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2032
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06173076
Lead sponsor
Shen Chun-Hong
Responsible party
Shen Chun-Hong (Associate Senior Doctor, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Sponsor-investigator
First posted
Dec 15, 2023
Start date
May 18, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Aug 27, 2025

Study contacts

Mei-Ping Ding
Contact
dmp-neurology@zju.edu.cn
+86 0571 87783872
Chun-Hong Shen
principal investigator · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion